Stay updated on Immunotherapy +/- EGFR Inhibitor in Advanced cSCC Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy +/- EGFR Inhibitor in Advanced cSCC Clinical Trial page.

Latest updates to the Immunotherapy +/- EGFR Inhibitor in Advanced cSCC Clinical Trial page
- Check5 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed information about cutaneous squamous cell carcinoma (cSCC) and the addition of new collaborators and a revision note. The core content related to cSCC treatment and prognosis has been largely deleted, which may impact the comprehensiveness of the information provided.SummaryDifference62%
- Check12 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check20 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check27 days agoNo Change Detected
- Check56 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check70 days agoChange DetectedThe webpage now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.8%
- Check78 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.0%
Stay in the know with updates to Immunotherapy +/- EGFR Inhibitor in Advanced cSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy +/- EGFR Inhibitor in Advanced cSCC Clinical Trial page.